Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V(2)) Therapy

Standard treatment regimens for the management of patients with refractory splenic marginal zone lymphoma (SMZL) are currently unavailable. Here, we report a case of SMZL, which, after failing multiple therapeutics, demonstrated an impressive clinical response to combined Venetoclax and Velcade (V(2...

Descripción completa

Detalles Bibliográficos
Autores principales: Roche, Kyle C., DeRosa, Peter A., Liu, Min-Ling, Nava, Victor E., Aggarwal, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221762/
https://www.ncbi.nlm.nih.gov/pubmed/35735437
http://dx.doi.org/10.3390/curroncol29060328
_version_ 1784732702481580032
author Roche, Kyle C.
DeRosa, Peter A.
Liu, Min-Ling
Nava, Victor E.
Aggarwal, Anita
author_facet Roche, Kyle C.
DeRosa, Peter A.
Liu, Min-Ling
Nava, Victor E.
Aggarwal, Anita
author_sort Roche, Kyle C.
collection PubMed
description Standard treatment regimens for the management of patients with refractory splenic marginal zone lymphoma (SMZL) are currently unavailable. Here, we report a case of SMZL, which, after failing multiple therapeutics, demonstrated an impressive clinical response to combined Venetoclax and Velcade (V(2)), a treatment combination currently being investigated in the setting of refractory multiple myeloma. We also report a unique histopathology and mutational profile that may have important implications for the characterization and prognosis of SMZL.
format Online
Article
Text
id pubmed-9221762
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92217622022-06-24 Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V(2)) Therapy Roche, Kyle C. DeRosa, Peter A. Liu, Min-Ling Nava, Victor E. Aggarwal, Anita Curr Oncol Case Report Standard treatment regimens for the management of patients with refractory splenic marginal zone lymphoma (SMZL) are currently unavailable. Here, we report a case of SMZL, which, after failing multiple therapeutics, demonstrated an impressive clinical response to combined Venetoclax and Velcade (V(2)), a treatment combination currently being investigated in the setting of refractory multiple myeloma. We also report a unique histopathology and mutational profile that may have important implications for the characterization and prognosis of SMZL. MDPI 2022-06-06 /pmc/articles/PMC9221762/ /pubmed/35735437 http://dx.doi.org/10.3390/curroncol29060328 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Roche, Kyle C.
DeRosa, Peter A.
Liu, Min-Ling
Nava, Victor E.
Aggarwal, Anita
Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V(2)) Therapy
title Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V(2)) Therapy
title_full Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V(2)) Therapy
title_fullStr Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V(2)) Therapy
title_full_unstemmed Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V(2)) Therapy
title_short Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V(2)) Therapy
title_sort refractory splenic marginal zone lymphoma responsive to combination venetoclax and bortezomib (velcade) (v(2)) therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221762/
https://www.ncbi.nlm.nih.gov/pubmed/35735437
http://dx.doi.org/10.3390/curroncol29060328
work_keys_str_mv AT rochekylec refractorysplenicmarginalzonelymphomaresponsivetocombinationvenetoclaxandbortezomibvelcadev2therapy
AT derosapetera refractorysplenicmarginalzonelymphomaresponsivetocombinationvenetoclaxandbortezomibvelcadev2therapy
AT liuminling refractorysplenicmarginalzonelymphomaresponsivetocombinationvenetoclaxandbortezomibvelcadev2therapy
AT navavictore refractorysplenicmarginalzonelymphomaresponsivetocombinationvenetoclaxandbortezomibvelcadev2therapy
AT aggarwalanita refractorysplenicmarginalzonelymphomaresponsivetocombinationvenetoclaxandbortezomibvelcadev2therapy

Ejemplares similares